June 29, 2020 / 5:08 AM / 10 days ago

BRIEF-Novo Nordisk: Rybelsus Approved In Japan

June 29 (Reuters) - Novo Nordisk A/S:

* REG-RYBELSUS® APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES

* JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED RYBELSUS(®) (ORAL SEMAGLUTIDE)

* WILL NOW INITIATE REIMBURSEMENT NEGOTIATIONS AND EXPECTS TO LAUNCH RYBELSUS(®) IN JAPAN THEREAFTER

* JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED RYBELSUS(®) (ORAL SEMAGLUTIDE) FOR TREATMENT OF ADULTS WITH TYPE 2 DIABETES. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below